Sam Janes

UCL

Sam won an MRC Training Fellowship to perform a PhD and then a post-doctoral period working in the CRUK Lincoln’s Inn Fields Institute with Fiona Watt working on integrin adhesion molecules and cancer cell survival. He then moved as an MRC Clinician Scientist to UCL leading a group interested in the role of stem cells in lung cancer pathogenesis and treatment of lung disease using cell therapies. He was awarded a Wellcome Trust Senior Clinical Fellowship in October 2010 to work on novel cell therapies for lung cancers resulting in a DPFS first-in-man award and recently won his Wellcome Senior Fellowship renewal to study the genetic and cellular changes lung cancer pathogenesis. The ambition is that from this knowledge he can develop therapies detecting and targeting early lung cancers and thereby dramatically improve outcomes.

He works as a respiratory consultant at UCLH with a particular interest in Lung Cancer, mesothelioma, interventional and diagnostic bronchoscopy and early lung cancer detection. He is Head of Respiratory Research Department at UCL, director of the Lung Cancer Board for London Cancer, lead for Pulmonary at the International Society of Cellular Therapies and Vice-Chair of the National ‘Clinical Expert Group’ on Lung Cancer.

dont miss

Early Detection of Lung Cancer

Unlike most cancers there has been little progress in cure rates for lung cancer over the past two decades. It has become clear that the key drive for research must be to detect lung cancers early, or, even better, detect those at risk of developing the disease.

EVEN MORE SEMINARS

  • Chris Curtis: Speaking at the Oncology Convention

    Chris Curtis
    The Swallows Head & Neck Cancer Charity

    A patient’s journey ‘Cancer to the palace in 6yrs’

  • Glenn Flux: Speaking at the Oncology Convention

    Glenn Flux
    Royal Marsden Hospital

    The emergence and resurgence of radiotherapeutics for cancer treatment

  • Philip Beer MRCP, FRCPath, PhD: Speaking at the Oncology Convention

    Philip Beer MRCP, FRCPath, PhD
    ONCODNA S.A

    The evolution of oncology therapeutics in the genomic era.

  • Michael Schreiber: Speaking at the Oncology Convention

    Michael Schreiber
    Brain Tumor Foundation, Chairman

    Brain Tumors - Innovation, support and advocacy

  • Michiel van den Brekel: Speaking at the Oncology Convention

    Michiel van den Brekel
    The Netherlands Cancer Institute

    Vocal and pulmonary rehabilitation after total laryngectomy